Jeuveau is the newest member of the family of neuromodulators, and was FDA-approved for wrinkles in February 2019. Like Botox, Dysport, and Xeomin, Jeuveau is used to temporarily improve the appearance of frown lines between the eyebrows — (called the glabellar lines, but often referred to as the “11s.” It can also be used to treat other areas, like crow’s feet around the eyes and smile lines. Like Botox, Jeuveau has a molecular weight of 900 kDa, but they’re produced in different facilities and are derived from different strains of the same toxin. (Botox, or onabotulinumtoxinA, is made by Allergan in Westport, Ireland; Jeuveau, or prabotulinumtoxinA, comes out of Seoul, South Korea.) The risks and potential side effects listed by the companies are also identical.